Search results
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
Zacks via Yahoo Finance· 10 months agoAtreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation,...
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation,...